Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres"

Related Experiment Video

Updated: May 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Bruno Sangro, Mercedes Iñarrairaegui, Jose I Bilbao

    Journal of Hepatology
    |January 17, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    Related Experiment Videos

    Last Updated: May 15, 2026

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.

    Liver cancer·2026

    First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

    Journal of hepatology·2026

    First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

    Future oncology (London, England)·2026

    Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.

    JHEP reports : innovation in hepatology·2026

    Invasive fungal infections after liver transplantation: Risk factors and impact on mortality in a retrospective single-center cohort with propensity score matching.

    Medicina clinica·2026

    Ultra-low-pass whole-genome sequencing of bile cfDNA in patients with biliary strictures.

    eGastroenterology·2026

    Crosstalk along the gut-liver axis in liver disease: Clinical and mechanistic aspects.

    Journal of hepatology·2026

    Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ macrophages.

    Journal of hepatology·2026

    Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.

    Journal of hepatology·2026

    Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis.

    Journal of hepatology·2026

    Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation.

    Journal of hepatology·2026

    Calcaneal tuberosity avulsion fracture fixation: a technical note and results on cases of patients.

    Frontiers in surgery·2026

    Synthetic preimplantation factor ameliorates the severity of radiotherapy-induced heart disease in a rat model.

    Frontiers in cardiovascular medicine·2026

    Nocturnal sleep duration, clinical activity score, and thyroid functional remission after radioactive iodine therapy in Graves' disease with thyroid-associated ophthalmopathy.

    Frontiers in endocrinology·2026

    A multicenter, prospective, phase 2 trial on proton re-irradiation for patients with previously treated head and neck cancer.

    Cancer·2026

    Meeting the Need: Development of a Theranostics-Focused Nuclear Oncology Physics Fellowship.

    International journal of radiation oncology, biology, physics·2026

    Hormone replacement after radiotherapy for premenopausal patients with cervical cancer: a retrospective cohort study.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us